<DOC>
	<DOCNO>NCT00545935</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy profile new paediatric MB formulation combine AQ AS compare AS-AQ young African child uncomplicated falciparum malaria .</brief_summary>
	<brief_title>Safety Efficacy Methylene Blue Combined With Amodiaquine Artesunate Malaria Treatment Children Burkina Faso</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>0.55 year ( 659 month ) old child uncomplicated malaria cause P. falciparum asexual parasite ≥ 2000/µ ≤ 200000/µ axillary temperature ≥ 37.5 Celsius history fever last 24 hour Burkinabe nationality inform consent complicate severe malaria apparent significant disease anaemia ( haematocrit &lt; 21 % ) treat trial modern antimalarial treatment prior inclusion ( last three day ) , except child treat chloroquine</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>